Abbott Laboratories Stock Forecast for 2022 - 2025 - 2030

Updated on 05/24/2022

Stock Rating
7 / 10
Price Target
$140.00
Consensus
Outperform
Upside
23.06%
Analysts
19
Stock Rating
7
Upside
23.06%
Analysts
19
Price Target
$140.00

Abbott Laboratories's stock price reaches the average target of $140.00 by 2023 as expected recently by nineteen notable experts, there would be a potential upside of approximately 23.06% from the last closing price in May, 2022. This possible increase is based on a high estimate of $151.00 and a low estimate of $104.00. If you are interested in ABT stock, it is important to also consider its competitors.

$140.00

23.06% Upside

Outperform
Outperform

Abbott Laboratories Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Abbott Laboratories's Fair Value has grown by 80.9%, rising from $75.77 to $137.08. For the following year, the 22.00 analysts predict that ABT's Fair Value will drop by 6.72%, reaching $242.06. Over the next nine years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 76.59%.

2022 Fair Value Forecast
$127.87
2023 Fair Value Forecast
$131.55
2024 Fair Value Forecast
$145.49
2025 Fair Value Forecast
$160.49
2026 Fair Value Forecast
$174.96
2027 Fair Value Forecast
$190.82
2028 Fair Value Forecast
$207.31
2029 Fair Value Forecast
$224.26
2030 Fair Value Forecast
$242.06
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
LLY Stock Forecast Eli Lilly and Outperform 5
$305.96 $281.95 4.92% 12
AZN Stock Forecast AstraZeneca PLC Outperform 3
£104.94 £136.08 39% 13
DHR Stock Forecast Danaher Outperform 5
$252.00 $339.17 32.94% 7
GSK Stock Forecast GlaxoSmithKline Outperform 1
£17.64 £16.08 2.04% 11
AMAT Stock Forecast Applied Materials Outperform 7
$106.59 $161.48 34.63% 2

Abbott Laboratories Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Abbott Laboratories's Revenue has grown by 40.87%, rising from $30.58B to $43.08B. For the following year, the 20.00 analysts predict that ABT's Revenue will drop by 3.35%, reaching $61.87B. Over the next nine years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 43.62%.

2022 Rev Forecast
$41.63B
2023 Rev Forecast
$41.39B
2024 Rev Forecast
$44.20B
2025 Rev Forecast
$46.58B
2026 Rev Forecast
$49.65B
2027 Rev Forecast
$52.57B
2028 Rev Forecast
$55.53B
2029 Rev Forecast
$58.68B
2030 Rev Forecast
$61.87B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CSL Stock Forecast CSL Outperform 4
$266.28 $228.01 -14.01% 10
MMM Stock Forecast 3M Hold 5
$145.75 $188.41 9.98% 17
BDX Stock Forecast Becton, Dickinson and Outperform 5
$257.45 $270.20 10.7% 3

Abbott Laboratories Dividend per Share Forecast for 2022 - 2025 - 2030

In the past three years, Abbott Laboratories's DPS has seen significant growth, rising from $1.16 to $1.82 – a growth of 56.9%. In the following year, the 10.00 analysts surveyed believe that ABT's DPS will decrease by 0.55%, reaching a dismal $4.15. For the next nine years, the forecast is for DPS to grow by 128.26%.

2022 DPS Forecast
$1.81
2023 DPS Forecast
$1.96
2024 DPS Forecast
$2.11
2025 DPS Forecast
$2.53
2026 DPS Forecast
$2.78
2027 DPS Forecast
$3.08
2028 DPS Forecast
$3.45
2029 DPS Forecast
$3.78
2030 DPS Forecast
$4.15
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14
CL Stock Forecast Colgate-Palmolive Hold 5
$78.12 $84.90 4.97% 9
EW Stock Forecast Edwards Lifesciences Outperform 5
$94.54 $127.85 37.51% 19

Abbott Laboratories Free Cash Flow Forecast for 2022 - 2025 - 2030

Abbott Laboratories's Free Cash Flow has seen impressive growth in the last three years, rising from $4.91B to $8.65B – a growth of 76.27%. In the next year, analysts believe that Free Cash Flow will reach an unimpressive $9.29B – an increase of 7.42%. For the next nine years, the forecast is for Free Cash Flow to grow by 24.85%.

2022 FCF Forecast
$9.29B
2023 FCF Forecast
$8.56B
2024 FCF Forecast
$9.04B
2025 FCF Forecast
$9.48B
2026 FCF Forecast
$9.58B
2027 FCF Forecast
$9.93B
2028 FCF Forecast
$10.23B
2029 FCF Forecast
$10.49B
2030 FCF Forecast
$10.80B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BSX Stock Forecast Boston Scientific Outperform 4
$40.15 $49.85 24.53% 23
GIS Stock Forecast General Mills Hold 2
$69.14 $67.53 -1.65% 18
4568 Stock Forecast Daiichi Sankyo Company Outperform 2
¥2.83k ¥0.00 36.07% 0

Abbott Laboratories Net Income Forecast for 2022 - 2025 - 2030

Abbott Laboratories's Net Income has seen astonishing growth in the last three years, rising from $2.37B to $7.07B – a growth of 198.61%. In the next year, analysts believe that Net Income will reach a reasonable $8.64B – an increase of 22.21%. For the next nine years, experts predict that Abbott Laboratories's Net Income will grow at a rate of 131.06%.

2022 NI Forecast
$8.64B
2023 NI Forecast
$8.79B
2024 NI Forecast
$9.75B
2025 NI Forecast
$10.69B
2026 NI Forecast
$11.74B
2027 NI Forecast
$12.82B
2028 NI Forecast
$13.94B
2029 NI Forecast
$15.12B
2030 NI Forecast
$16.34B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3
A Stock Forecast Agilent Technologies Outperform 7
$124.41 $172.40 28.61% 2
BN Stock Forecast Danone Hold 4
54.87€ 62.59€ 2.06% 18

Abbott Laboratories EBITDA Forecast for 2022 - 2025 - 2030

In the past three years, Abbott Laboratories's EBITDA has grown by 79.26%, rising from $7.12B to $12.76B. Over the next nine years, experts believe that ABT's EBITDA will grow at a rate of 43.22%.

2022 EBITDA Forecast
$12.00B
2023 EBITDA Forecast
$11.94B
2024 EBITDA Forecast
$13.15B
2025 EBITDA Forecast
$12.29B
2026 EBITDA Forecast
$13.49B
2027 EBITDA Forecast
$14.61B
2028 EBITDA Forecast
$15.76B
2029 EBITDA Forecast
$17.01B
2030 EBITDA Forecast
$18.27B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
EDF Stock Forecast Electricité de France Outperform 4
8.41€ 14.68€ 13.67% 9
4503 Stock Forecast Astellas Pharma Outperform 2
¥1.80k ¥0.00 33.33% 0
DXCM Stock Forecast DexCom Buy 0
$288.13 $560.79 82.21% 3

Abbott Laboratories EBIT Forecast for 2022 - 2025 - 2030

In the last three years, Abbott Laboratories's EBIT has seen significant growth, surging from $3.84B to $9.22B – an increase of 140.18%. In the next year, analysts predict that EBIT will jump to $10.33B – up 12.07% from the current level. Looking ahead to nine years, experts forecast that EBIT will grow by 112.71%.

2022 EBIT Forecast
$10.33B
2023 EBIT Forecast
$10.32B
2024 EBIT Forecast
$11.31B
2025 EBIT Forecast
$12.07B
2026 EBIT Forecast
$13.81B
2027 EBIT Forecast
$15.08B
2028 EBIT Forecast
$16.45B
2029 EBIT Forecast
$18.06B
2030 EBIT Forecast
$19.61B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
7751 Stock Forecast Canon Hold 2
¥2.64k ¥0.00 14.9% 0
CHD Stock Forecast Church & Dwight Hold 5
$90.43 $88.52 9.48% 9
CAH Stock Forecast Cardinal Health Hold 5
$57.11 $57.23 1.56% 4

Abbott Laboratories EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Abbott Laboratories's EPS has grown by 80.9%, rising from $2.88 to $5.21. For the following year, the 22.00 analysts predict that ABT's EPS will drop by 6.72%, reaching $9.20. Over the next nine years, experts predict that Abbott Laboratories's EPS will grow at a rate of 76.59%.

2022 EPS Forecast
$4.86
2023 EPS Forecast
$5.00
2024 EPS Forecast
$5.53
2025 EPS Forecast
$6.10
2026 EPS Forecast
$6.65
2027 EPS Forecast
$7.25
2028 EPS Forecast
$7.88
2029 EPS Forecast
$8.52
2030 EPS Forecast
$9.20
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BIO Stock Forecast Bio-Rad Laboratories Outperform 7
$518.73 $701.33 34.94% 2
TECH Stock Forecast Bio-Techne Outperform 3
$357.17 $528.73 39.99% 11
4523 Stock Forecast Eisai Hold 0
¥6.85k ¥0.00 -3.61% 0

© Copyright 2022 | Stock Forecast | All Rights Reserved